Clinical parameters affecting the therapeutic efficacy of empagliflozin in patients with type 2 diabetes

PloS One
Yun Kyung ChoWoo Je Lee

Abstract

We aimed to investigate the clinical factors affecting the therapeutic effectiveness of the sodium-glucose cotransporter-2 inhibitor empagliflozin in patients with type 2 diabetes mellitus (T2DM). We reviewed the medical records of 374 T2DM patients aged between 20 and 75 years who were prescribed empagliflozin 10 mg or 25 mg as add-on therapy for more than 90 consecutive days. Changes in hemoglobin A1c (HbA1c) from baseline levels and the reduction in body weights of the study participants were assessed. We found that younger patients (≤ 50 years), patients with the highest levels of HbA1c (>9%) at baseline, patients with an estimated glomerular filtration rate (eGFR) of >90 mL/min/1.73 m2, and patients with a shorter duration of T2DM (< 10 years) were more likely to exhibit a better glycemic response. Multivariate linear regression analysis revealed that a shorter duration of T2DM, higher baseline levels of HbA1c, and higher eGFR were positively associated with HbA1c reduction. Higher BMI and lower HbA1c levels were predictors of a more significant reduction in body weight among patients taking empagliflozin. The glucose-lowering effect of empagliflozin was more evident in T2DM patients with higher baseline HbA1c levels, bett...Continue Reading

References

May 29, 2010·Nature Reviews. Drug Discovery·Edward C Chao, Robert R Henry
Sep 13, 2013·Annals of Internal Medicine·Despoina VasilakouApostolos Tsapas
Apr 12, 2014·Diabetes Care·Hans-Ulrich HäringUNKNOWN EMPA-REG MET Trial Investigators
Nov 27, 2014·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Sanjay Kalra
Mar 19, 2015·TheScientificWorldJournal·L ZanoliP Castellino
Nov 1, 2017·Diabetes & Metabolism Journal·Seung Hyun KoUNKNOWN Committee of Clinical Practice Guideline of Korean Diabetes Association
Dec 10, 2017·Diabetes Care·UNKNOWN American Diabetes Association
Sep 27, 2018·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·P C LeeS-Y Goh

❮ Previous
Next ❯

Citations

Feb 5, 2021·Diabetes Care·Nishi Chaturvedi, Sophie Eastwood
Mar 24, 2021·Family Practice·Hanifah DavisThomas Delate

❮ Previous
Next ❯

Software Mentioned

SPSS

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.